Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 5, 2016
Having a price of $5.43, Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) traded 3.63% higher on the day. With the last stock price up 39.25% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. DRNA has recorded a 50-day average of $3.76 and a two hundred day average of $3.90. Trade Volume was up over the average, with 308,209 shares of DRNA changing hands over the typical 266,212
Zacks Investment Research has downgraded Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to Hold in a statement released on Wednesday October 05, 2016.
On 10/04/2016, Zacks Investment Research released a statement about Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) upped the target price from $0.00 to $6.00 that suggested an upside of 0.10%.
Recent Performance Chart
Dicerna Pharmaceuticals Inc has with a one year low of $2.69 and a one year high of $15.93 and has a market capitalization of $0.
A total of 4 brokerages have issued a ratings update on Dicerna Pharmaceuticals Inc. Three brokerages rating the company a strong buy, one brokerage rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $14.50.
General Company Details For Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.